Edwards Lifesciences Co. (NYSE:EW) Shares Sold by First Financial Corp IN

First Financial Corp IN reduced its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 10.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,204 shares of the medical research company’s stock after selling 147 shares during the period. First Financial Corp IN’s holdings in Edwards Lifesciences were worth $89,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. FSA Wealth Management LLC acquired a new stake in Edwards Lifesciences during the third quarter worth approximately $30,000. Prospera Private Wealth LLC acquired a new stake in shares of Edwards Lifesciences during the third quarter worth $32,000. Avior Wealth Management LLC grew its position in shares of Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares during the period. Peoples Bank KS acquired a new position in Edwards Lifesciences in the third quarter valued at $40,000. Finally, JFS Wealth Advisors LLC increased its stake in Edwards Lifesciences by 31.1% in the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 166 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Trading Down 3.0 %

Shares of EW opened at $71.20 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The stock has a 50-day moving average price of $71.73 and a 200 day moving average price of $71.77. The company has a market capitalization of $41.99 billion, a P/E ratio of 10.27, a P/E/G ratio of 3.61 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.67. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.59 earnings per share. Sell-side analysts forecast that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Insider Activity

In related news, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the transaction, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. The trade was a 9.63 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 32,500 shares of company stock worth $2,160,800. 1.29% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

EW has been the subject of several recent analyst reports. JPMorgan Chase & Co. lifted their price target on Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a report on Friday, October 25th. Barclays boosted their target price on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the company an “overweight” rating in a report on Monday, December 2nd. Citigroup increased their price target on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Evercore ISI lowered their price objective on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a research note on Tuesday, October 1st. Finally, Stifel Nicolaus increased their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the stock a “hold” rating in a research report on Thursday, December 5th. Sixteen equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences presently has an average rating of “Hold” and an average target price of $79.40.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.